SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA) is trending as its high-performance, compliance-first Layer 1 network, validated at over 11 million transactions per second, integrates a live fiat anchor with Bridge, a Stripe company. This partnership enables seamless, regulated movements of traditional currencies and stablecoins, positioning KTA as crucial financial plumbing for institutional adoption in global payments. The community is actively discussing KTA's significant potential and perceived undervaluation, viewing it as an asymmetric opportunity in the evolving digital finance landscape.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending amidst a community divided between strong bullish sentiment anticipating a significant price breakout and those questioning its long-term relevance. Many proponents highlight its established role as 'digital silver' for transactions, while others emphasize the emergence of high-performance Layer 1 networks like Keeta, which are attracting attention for institutional-grade financial infrastructure and integrated fiat on-ramps.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp ($OMER) is trending due to the landmark FDA approval of YARTEMLEA, making it the first and only approved treatment for the life-threatening transplant-associated thrombotic microangiopathy (TA-TMA) in both adults and children. The community is buzzing with excitement over the stock's perceived undervaluation and significant upside potential, fueled by its strengthened pipeline and existing partnership with Novo Nordisk. Many anticipate further gains as investors discuss a potential short squeeze and future buyout prospects for this newly de-risked asset.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is trending due to positive news on significant regulatory relief, including the lifting of a key consent order, alongside a strong earnings report that reinforced confidence in its ongoing transformation strategy. The community is actively debating if the stock's remarkable appreciation, which has seen it reach multi-year highs, is sustainable amidst discussions of overbought technical levels, despite a broader optimistic outlook for the financial sector.

iRhythm Technologies, Inc. is a digital healthcare company, which engages in the provision of design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. It also provides solutions that detect, predict, and prevent disease. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.

iRhythm Technologies Inc

iRhythm Technologies is generating significant buzz following a flurry of bullish analyst upgrades and compelling AMALFI study data that validates the superior performance of its Zio service for AFib detection. The community is actively discussing this strong fundamental and institutional interest, which appears to be outweighing recent bearish sentiment, highlighting the company's innovation in the digital cardiac monitoring space. This momentum is further supported by recent positive earnings and strategic operational advancements, positioning IRTC as a key player in healthcare technology.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Agios Pharmaceuticals is a major topic after its drug Aqvesme (mitapivat) secured FDA approval as the only therapy for alpha- and beta-thalassemia, tapping into a significant patient population. While this milestone is driving considerable optimism and discussions of upward potential within the community, some investors are weighing its label, which includes a Risk Evaluation and Mitigation Strategy (REMS), against the stock's recent price movements. This approval marks a key moment, particularly after earlier mixed results from a different clinical program.

Dycom Industries, Inc. provides contracting services throughout the United States. Its services include engineering, construction, maintenance and installation services to telecommunications providers, underground facility locating services to various utilities, including other construction and maintenance services to electric and gas utilities, and others. The company was founded in 1969 and is headquartered in West Palm Beach, FL.

Dycom Industries, Inc.

Dycom Industries is experiencing significant momentum following its strategic acquisition of Power Solutions, bolstering its capabilities in digital infrastructure and data center construction for AI-driven demand. The community is bullish on the company's strong earnings and record backlog, highlighting its prime position to capitalize on extensive fiber deployment and BEAD program funding, which has led to widespread analyst upgrades and optimistic market sentiment.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is trending as Sanofi moves to acquire the company, aiming to bolster its adult immunization portfolio with Dynavax's hepatitis B vaccine and a promising shingles candidate. While many long-term investors express relief, a notable sentiment within the community is disappointment regarding the acquisition value, with discussions around past management actions and the potential for competing offers.

TOSHI

TOSHI is buzzing with community chatter, driven by its recent major exchange listing and ongoing development within the Base ecosystem, including new utility features. Despite market fluctuations, holders express strong conviction, actively accumulating the token and anticipating substantial future growth as the "Face of Base."

Aptos is a new, independent high-performance PoS Layer 1 project focused on delivering the safest and most scalable Layer 1 blockchain in the world. The Aptos blockchain leverages the Move programming language and the Move VM for application development, which are created and optimized for blockchain use cases.The team is comprised of the original creators, researchers, designers, and builders of Diem, the blockchain that was first built to serve this purpose. Aptos raised $200m from a16z, Multicoin, Binance and others. Aptos launched Devnet in mid March, incentivized testnet in late May and targets Q3 for mainnet launch.

Aptos

Aptos is trending due to a flurry of ecosystem developments and strategic integrations, particularly its booming stablecoin market exceeding $1 billion and robust growth in Real World Asset tokenization with key institutional participation. The community highlights its foundational technology, leveraging former Meta expertise for high performance and scalability, positioning it as a leading Layer 1 network for future financial infrastructure. Enthusiasm is high for its role in enabling high-speed, compliant transactions and cross-chain liquidity across the broader digital economy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Assenagon Asset Management S.A. Sells 250,594 Shares of Pacira BioSciences, Inc. $PCRX

Assenagon Asset Management S.A. decreased its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 51.9% in the 3rd quarter, according to its most recent 13F filing with the...

5 Biotech Stocks to Watch for Potential Upside

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position ARQT, FOLD, ANIP, TNGX and PCRX in this volatile sector. 

EcoR1 Capital LLC Acquires New Position in Pacira BioSciences, Inc. $PCRX

EcoR1 Capital LLC bought a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange...

Insider Selling: Pacira BioSciences (NASDAQ:PCRX) CFO Sells 9,104 Shares of Stock

Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) CFO Shawn Cross sold 9,104 shares of the business's stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an...

Pacira BioSciences (NASDAQ:PCRX) CFO Shawn Cross Sells 15,896 Shares

Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) CFO Shawn Cross sold 15,896 shares of the business's stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an...

Shawn Cross Sells 15,896 Shares of Pacira BioSciences (NASDAQ:PCRX) Stock

Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) CFO Shawn Cross sold 15,896 shares of Pacira BioSciences stock in a transaction on Tuesday, December 9th. The shares were sold at an average...

Natixis Buys 151,250 Shares of Pacira BioSciences, Inc. $PCRX

Natixis grew its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 302,500.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and...

Russell Investments Group Ltd. Sells 5,703,634 Shares of Pacira BioSciences, Inc. $PCRX

Russell Investments Group Ltd. reduced its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 98.4% during the second quarter, according to its most recent Form 13F filing with the...

Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Rating of "Hold" from Analysts

Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) has been assigned an average recommendation of "Hold" from the seven brokerages that are presently covering the stock, MarketBeat.com reports...

Pacira BioSciences (NASDAQ:PCRX) Coverage Initiated by Analysts at Barclays

Barclays initiated coverage on Pacira BioSciences in a report on Tuesday. They issued an "equal weight" rating and a $27.00 price target for the company...

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Current Price	$26.02
Prev Close	$25.74
Open	$25.62
Dividend Yield	0.00%
50-Day Moving Average	$23.56
Beta	0.39
Avg. Volume	803,988.68
PE Ratio	57.70

52-Week High	$27.64
52-Week Low	$18.17
Market Capitalization	$1.11B
EPS (Annual)	-$2.15
Price to Book	1.52
Revenue Per Employee	$887,298.73
Enterprise Value/EBITDA	N/A

PCRX
Pacira BioSciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PCRX News

PCRXPacira BioSciences Inc